Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tango Therapeutics ( (TNGX) ) has provided an announcement.
On October 23, 2025, Tango Therapeutics announced preliminary unaudited financial results, estimating $152.8 million in cash and marketable securities as of September 30, 2025. The company also provided a clinical update on its ongoing Phase 1/2 trial of vopimetostat, highlighting its potential as a best-in-class treatment for MTAP-deleted solid tumors, with plans for a pivotal study in second-line pancreatic cancer to begin in 2026.
The most recent analyst rating on (TNGX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
The overall stock score for Tango Therapeutics is primarily impacted by its financial performance, which is currently weak due to declining revenues and persistent losses. Technical analysis provides a more positive outlook with bullish indicators, but the negative valuation metrics, including a negative P/E ratio, weigh down the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Tango Therapeutics is a company in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is working on a product pipeline that includes vopimetostat, an oral PRMT5 inhibitor, which is being developed to treat multiple common cancers, including pancreatic and lung cancer.
Average Trading Volume: 2,039,115
Technical Sentiment Signal: Buy
Current Market Cap: $1B
See more insights into TNGX stock on TipRanks’ Stock Analysis page.